Article Information
History
- December 27, 2021.
Article Versions
- You are currently viewing Version 1 of this article (December 27, 2021 - 11:52).
- Version 2 (February 14, 2022 - 08:30).
- Version 3 (February 21, 2022 - 13:12).
- View Version 4, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.
Author Information
- Wataru Ogura1,¶,
- Kouki Ohtsuka2,¶,*,
- Sachiko Matsuura1,
- Takahiro Okuyama1,
- Satsuki Matsushima2,
- Satoko Ymasaki2,
- Hiroyuki Miyagi1,
- Kumiko Sekiguchi1,
- Hiroaki Ohnishi2 and
- Takashi Watanabe2
- 1Department of Clinical Laboratory, Kyorin University Hospital, Mitaka, Tokyo, Japan
- 2Department of Laboratory Medicine, Kyorin University School of Medicine, Mitaka, Tokyo, Japan
- ↵*Corresponding author E-mail: kouki7{at}ks.kyorin-u.ac.jp (KO)
↵¶ These authors contributed equally to this work.
Posted December 27, 2021.
Can individuals with low antibody responses to vaccines against other viruses acquire adequate SARS-CoV-2 antibody after vaccination with the BNT162b2 mRNA vaccine?
